Will Sanofi's Lantus Survive Cancer Scare? Studies Suggest a Worrisome Link
This article was originally published in The Pink Sheet Daily
Executive Summary
But the data also suggest a higher cancer risk could be due to "patient characteristics," and not Lantus itself.
You may also be interested in...
FDA Notes Lack Of Proof For Cancer Risk, But Lantus Isn't Out Of The Woods Yet
Commercial impact on the top-selling insulin is questionable, as 2009 studies showing the risk had already been seen as sketchy and did not appear to dent sales or competitive profile.
FDA Notes Lack Of Proof For Cancer Risk, But Lantus Isn't Out Of The Woods Yet
Commercial impact on the top-selling insulin is questionable, as 2009 studies showing the risk had already been seen as sketchy and did not appear to dent sales or competitive profile.
Sanofi-Aventis Licenses CureDM's Early-Stage Diabetes Compound To Bolster Pipeline
Privately-held CureDM could receive up to $335 million in payments, plus sales royalties, from Sanofi-Aventis.